OrbiMed, a US-based life sciences investment firm, has closed its fourth Asia-focused healthcare fund after garnering $800 million in commitments, surpassing its $750 million target.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
